NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS ...

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...
The Cardiology Advisor

AHA Scientific Statement Links Mitochondrial Genetic Variants to CVD

Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.

Tisento Therapeutics Completes Enrollment in PRIZM, a Global Phase 2b Study of Zagociguat for the Treatment of MELAS

Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...
Pharmabiz

NRG Therapeutics doses its first-in-human phase 1 trial for NRG5051 to treat ALS/MND and Parkinson’s disease

Stevenage, United Kingdom Saturday, January 10, 2026, 14:00 Hrs [IST] ...
TipRanks on MSN

Thiogenesis to showcase mitochondrial disease clinical progress at UMDF webinar

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will present ...